Display options
Share it on

Transfus Med Rev. 2021 Oct 10; doi: 10.1016/j.tmrv.2021.09.001. Epub 2021 Oct 10.

Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.

Transfusion medicine reviews

Ryan Ruiyang Ling, Jackie Jia Lin Sim, Felicia Liying Tan, Bee Choo Tai, Nicholas Syn, Sharavan Sadasiv Mucheli, Bingwen Eugene Fan, Saikat Mitra, Kollengode Ramanathan

Affiliations

  1. Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore.
  2. Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore.
  3. Department of Infectious Diseases, Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore.
  4. Deparment of Haematology, Tan Tock Seng Hospital, Singapore.
  5. Lyell McEwin Hospital, Adelaide, South Australia, Australia.
  6. Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore; Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore. Electronic address: [email protected].

PMID: 34782209 PMCID: PMC8502250 DOI: 10.1016/j.tmrv.2021.09.001

Abstract

Current evidence from randomized controlled trials (RCTs) and systematic reviews on the utility of convalescent plasma (CP) in patients with coronavirus disease 2019 (COVID-19) suggests a lack of benefit. We conducted an updated meta-analysis of RCTs with trial sequential analysis to investigate whether convalescent plasma is futile in reducing mortality in patients hospitalized with COVID-19. We searched 6 databases from December 1, 2019 to August 1, 2021 for RCTs comparing the use of CP with standard of care or transfusion of non-CP standard plasma in patients with COVID-19. The risk of bias was assessed using the Cochrane Risk-of-Bias 2 Tool. Random effects (DerSimonian and Laird) meta-analyses were conducted. The primary outcome was the aggregate risk for in-hospital mortality between both arms. We conducted a trial sequential analysis (TSA) based on the pooled relative risks (RRs) for in-hospital mortality. Secondary outcomes included the pooled RR for receipt of mechanical ventilation and mean difference in hospital length of stay. We included 18 RCTs (8702 CP, 7906 control). CP was not associated with a significant mortality benefit (RR: 0.95, 95%-CI: 0.86-1.04, P = .27, high certainty). Subgroup analysis did not find any significant differences (p

Copyright © 2021. Published by Elsevier Inc.

Keywords: Convalescent plasma; Coronavirus disease 2019; Meta-analysis; Mortality; Severe acute respiratory syndrome coronavirus 2

References

  1. PLoS Med. 2021 Mar 3;18(3):e1003415 - PubMed
  2. Clin Infect Dis. 2017 Nov 13;65(11):1843-1847 - PubMed
  3. J Clin Invest. 2021 Oct 15;131(20): - PubMed
  4. Emerg Infect Dis. 2016 Sep;22(9):1554-61 - PubMed
  5. JAMA Oncol. 2021 Jun 17;: - PubMed
  6. BMJ. 2009 Jul 21;339:b2535 - PubMed
  7. BMJ. 2011 Oct 18;343:d5928 - PubMed
  8. Crit Care Med. 2021 Jul 1;49(7):1015-1025 - PubMed
  9. N Engl J Med. 2021 Feb 18;384(7):610-618 - PubMed
  10. J Clin Epidemiol. 2011 Apr;64(4):383-94 - PubMed
  11. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  12. Eur Respir J. 2021 Aug 12;: - PubMed
  13. JAMA. 2021 Nov 2;326(17):1690-1702 - PubMed
  14. Infez Med. 2020 Sep 1;28(3):357-366 - PubMed
  15. BMJ. 2020 Sep 4;370:m3379 - PubMed
  16. PLoS One. 2021 Mar 25;16(3):e0249038 - PubMed
  17. Am J Pathol. 2021 Jan;191(1):90-107 - PubMed
  18. N Engl J Med. 2020 Apr 30;382(18):1708-1720 - PubMed
  19. BMJ. 2021 Jun 17;373:n1570 - PubMed
  20. Lancet. 2020 Mar 28;395(10229):1054-1062 - PubMed
  21. Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66 - PubMed
  22. J Infect Dis. 2015 Jan 1;211(1):80-90 - PubMed
  23. Nat Microbiol. 2020 Dec;5(12):1598-1607 - PubMed
  24. JAMA. 2021 Mar 23;325(12):1185-1195 - PubMed
  25. BMC Med Res Methodol. 2014 Dec 19;14:135 - PubMed
  26. Nat Med. 2021 Sep 9;: - PubMed
  27. N Engl J Med. 2021 Mar 18;384(11):1015-1027 - PubMed
  28. Ann Intern Med. 2006 Oct 17;145(8):599-609 - PubMed
  29. Nat Rev Neurol. 2015 Feb;11(2):80-9 - PubMed
  30. Int J Infect Dis. 2021 Aug;109:114-117 - PubMed
  31. Cochrane Database Syst Rev. 2021 May 20;5:CD013600 - PubMed
  32. BMJ. 2020 Oct 22;371:m3939 - PubMed
  33. JAMA. 2020 Aug 4;324(5):460-470 - PubMed
  34. Sci Rep. 2021 May 11;11(1):9927 - PubMed
  35. Mayo Clin Proc. 2021 May;96(5):1262-1275 - PubMed
  36. N Engl J Med. 2021 Feb 18;384(7):619-629 - PubMed
  37. J Clin Invest. 2021 Jul 1;131(13): - PubMed
  38. Intern Emerg Med. 2021 Nov;16(8):2181-2191 - PubMed

Publication Types